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2Chronic kidney disease (CKD) is a global health problem, estimated to affect over 500 
million people worldwide.1 Over 80% of the world’s CKD population live in low- and 
middle-income countries (LMICs).1 Current data suggest that the prevalence of CKD is rising 
globally and the demographic transitions driving this trend (such as hypertension and 
diabetes) disproportionately affect LMIC populations.2  The healthcare infrastructure in many 
LMICs is ill-equipped to cope with this rising burden of CKD.3 As a consequence, access to 
and resources for preventative strategies and early CKD care models are limited and lack 
efficacy.4 Without service provision strategies for early diagnosis and treatment of CKD, 
progression to end-stage renal failure (ESRF) is inevitable. This presents further challenges in 
terms of access to renal replacement therapy (RRT), healthcare costs and mortality.
The rising burden of progressive CKD in LMICs will be associated with an inevitable rise in 
CKD-related complications such as secondary hyperparathyroidism and CKD-mineral bone 
disease (CKD-MBD). CKD-MBD is characterised by abnormalities of calcium and 
phosphate homeostasis, endocrine feedback, bone turnover and extra-skeletal calcification. 
The management of CKD-MBD was revolutionised in the 1970s following the introduction 
of activated vitamin D3 (1-hydroxycholecalciferol and 1,25-dihydroxycholecalciferol) into 
clinical practice. Extreme phenotypes of the skeletal and extra-skeletal complications of 
CKD-MBD are now rarely encountered in developed countries. Advanced manifestations of 
CKD-MBD, however, are likely to be commonplace in LMICs where diagnosis of advanced 
CKD is likely to be delayed and resources, however simple, limited to manage its 
complications.
Here, we present two historical cases from a tertiary renal unit in Edinburgh, Scotland, which 
exemplify the skeletal and extra-skeletal manifestations of CKD-MBD and highlight the 
efficacy of activated vitamin D3 as a treatment to control these sequelae. Figure 1a (left 
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3panel) shows an X-ray of the left hand of a 27-year old female with ESRF due to reflux 
nephropathy. The X-ray was taken immediately prior to her commencing activated vitamin 
D3 therapy and demonstrates bone resorption of the terminal phalanges. Figure 1a (right 
Panel) shows the X-ray taken 5 months later and demonstrates remarkable bone remodelling, 
secondary to activated vitamin D3 therapy, most evident at the terminal phalanx of the 
second finger. Her plasma parathyroid hormone concentration fell from 4.1 to 1.2 µg/L over 
this period. The second case is of a 44-year old male with ESRF secondary to congenital 
renal dysplasia who started haemodialysis in 1964 at the age of 24. Figure 1b shows a 
photograph of his left eye with calcification of the corneal limbus demonstrated at the 5 and 8 
o’clock positions.
Although activated vitamin D3 analogues are inexpensive (c. £60 ($80) per patient year), they 
are one of the most efficacious drugs at our disposal; a fact that is easy to take for granted in 
the 21st century.  
                  
Figure 1a                                                                      Figure 1b
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